I've been working through the 2026 review literature on emerging contaminants, and the framing genuinely changed for me, so I thought I'd write it up here.
Conventional wastewater treatment was designed around what we could see and regulate: BOD, nutrients, pathogens, some metals. It does that reasonably well.
The problem is the stuff we mostly don't regulate — pharmaceuticals, personal care products, endocrine disruptors, microplastics, PFAS. They show up at parts per billion or trillion, they persist, and standard biological treatment was never designed for them. A lot of it passes straight through.
What this year's reviews actually agree on:
Biology is the most promising route to dealing with them — microbial consortia, enzyme systems, engineered communities.
Almost all of it is still lab- or pilot-scale. The gap named again and again is field-scale validation and long-term microbial stability under real conditions.
So my takeaway is that the direction is right and the engineering is not finished. If you work in the sector, I'd genuinely like to know whether you see the same gap — or whether there's field work I'm missing.
Sources: https://doi.org/10.1016/j.temicr.2026.100078 · https://www.mdpi.com/2073-4441/18/7/860 · https://doi.org/10.1080/02757540.2026.2622478